| Drug Type CAR-T | 
| Synonyms Anti-CD19-Car T cell therapy, PCAR 19B, pCAR-19B细胞自体回输制剂(Chongqing Precision Biotechnology) | 
| Target | 
| Action modulators | 
| Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) | 
| Therapeutic Areas | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseNDA/BLA | 
| First Approval Date- | 
| RegulationPriority Review (China), Breakthrough Therapy (China) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| CD19-positive B-cell acute lymphoblastic leukemia | NDA/BLA | China  | 20 Jul 2024 | |
| CD19 Positive B-Cell Leukemia | Phase 2 | China  | 26 Jan 2022 | |
| Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | China  | 26 Jan 2022 | |
| Systemic Lupus Erythematosus | Phase 1 | China  | 10 Feb 2024 | |
| CD19 positive Non-Hodgkin Lymphoma | Phase 1 | China  | 06 Sep 2021 | |
| Non-Hodgkin's lymphoma refractory | Phase 1 | China  | 06 Sep 2021 | |
| Recurrent Non-Hodgkin Lymphoma | Phase 1 | China  | 06 Sep 2021 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | China  | 30 Oct 2020 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | China  | 30 Oct 2020 | |
| Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | China  | 05 Nov 2019 | 
| NCT05334823 (ASH2024) Manual | Phase 2 | CD19-positive B-cell acute lymphoblastic leukemia CD19 Positive | 64 | fpyazftbvq(nisbkvbjpx) = kixhnsvjgr rlojmglsrq (ucfkbohpfg ) View more | Positive | 09 Dec 2024 | |
| Phase 1 | Pre B-cell acute lymphoblastic leukemia CD19 Positive | 9 | wpxlmskwla(wpxyzkrxqv) = foxssvexpj xfddlabwpz (nbydzmrnlm ) View more | Positive | 15 Nov 2022 | 





